226 related articles for article (PubMed ID: 10532639)
1. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
[TBL] [Abstract][Full Text] [Related]
2. Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.
Hartvig P; Lindner KJ; Tedroff J; Bjurling P; Hörnfelt K; Långström B
J Neural Transm Gen Sect; 1992; 87(1):15-22. PubMed ID: 1536715
[TBL] [Abstract][Full Text] [Related]
3. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on in vivo L-[beta-11C]dopa turnover in the rat striatum with infusion of L-tyrosine.
Tsukada H; Lindner KJ; Hartvig P; Tani Y; Bjurling P; Kihlberg T; Westerberg G; Watanabe Y; Långström B
J Neural Transm Gen Sect; 1994; 95(1):1-15. PubMed ID: 7857582
[TBL] [Abstract][Full Text] [Related]
4. L-DOPA modulates striatal dopaminergic function in vivo: evidence from PET investigations in nonhuman primates.
Tedroff J; Torstenson R; Hartvig P; Lindner KJ; Watanabe Y; Bjurling P; Westerberg G; Långström B
Synapse; 1997 Jan; 25(1):56-61. PubMed ID: 8987148
[TBL] [Abstract][Full Text] [Related]
5. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates.
Pate BD; Snow BJ; Hewitt KA; Morrison KS; Ruth TJ; Calne DB
J Nucl Med; 1991 Jun; 32(6):1246-51. PubMed ID: 1904482
[TBL] [Abstract][Full Text] [Related]
6. Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.
Tedroff J; Aquilonius SM; Hartvig P; Lundqvist H; Bjurling P; Långström B
Acta Neurol Scand; 1992 Mar; 85(3):166-73. PubMed ID: 1574997
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of radiotracers in human plasma during positron emission tomography.
Cumming P; Yokoi F; Chen A; Deep P; Dagher A; Reutens D; Kapczinski F; Wong DF; Gjedde A
Synapse; 1999 Nov; 34(2):124-34. PubMed ID: 10502311
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
10. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
11. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
13. The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain.
Hammerstad JP; Pate BD; Hewitt KA; Chan GL; Ruth TJ; Calne DB
Ann Neurol; 1993 Oct; 34(4):603-8. PubMed ID: 8215248
[TBL] [Abstract][Full Text] [Related]
14. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin and infusion of L-tyrosine on the in vivo L-[beta-11C] DOPA disposition in the monkey brain.
Tsukada H; Lindner KJ; Hartvig P; Tani Y; Valtysson J; Bjurling P; Kihlberg T; Westerberg G; Watanabe Y; Långström B
Brain Res; 1996 Mar; 713(1-2):92-8. PubMed ID: 8724979
[TBL] [Abstract][Full Text] [Related]
15. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
[TBL] [Abstract][Full Text] [Related]
16. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
17. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Wahl L; Nahmias C
J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
[TBL] [Abstract][Full Text] [Related]
18. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
19. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
20. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.
Tedroff J; Torstenson R; Hartvig P; Sonesson C; Waters N; Carlsson A; Neu H; Fasth KJ; Långström B
Synapse; 1998 Apr; 28(4):280-7. PubMed ID: 9517836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
